Literature DB >> 20399053

[Giant venous malformation of the tongue: the value of Surgiflo].

S Slaba1, C Braidy, R B Sader, N Hokayem, J Nassar.   

Abstract

Cavernous hemangiomas are rare congenital venous malformations having propensity for the head and neck. These venous malformations, especially the large and intraoral ones, may cause severe symptoms requiring aggressive treatment. Today, the main treatment is based on sclerotherapy, associated or no with surgery. We report on a patient presenting an enormous venous malformation of the face and tongue, which was treated successfully in our department by embolization, sclerotherapy and maxillo-facial surgery, with a special focus on Surgiflo in our technique.

Entities:  

Mesh:

Year:  2010        PMID: 20399053     DOI: 10.1016/j.jmv.2010.03.004

Source DB:  PubMed          Journal:  J Mal Vasc        ISSN: 0398-0499


  5 in total

1.  A cavernous hemangioma of the tongue base presenting as an ectopic thyroid: A case report.

Authors:  Dr M Beghdad; Dr K Choukry; Dr A Mkhatri; Dr Z El Krimi; Pr Y Oukessou; Pr S Rouadi; Pr R Abada; Pr M Roubal; Pr M Mahtar
Journal:  Ann Med Surg (Lond)       Date:  2020-10-23

2.  Cavernous hemangioma of the tongue: A rare case report.

Authors:  K A Kamala; L Ashok; G P Sujatha
Journal:  Contemp Clin Dent       Date:  2014-01

3.  Venous malformations management by Er,Cr:YSGG laser: An Alternative approach.

Authors:  Vinod Chandel; Babita Jangra; Nishant Khurana; Amit Garg
Journal:  Laser Ther       Date:  2017-12-31

4.  Rare localization of tongue vascular lesion detected by multi-parametric magnetic resonance imaging.

Authors:  Antonio Gilardi; Massimo Ralli; Andrea Colizza; Arianna Di Stadio; Daniela Messineo; Mara Riminucci; Alessandro Corsi; Antonio Greco; Marco de Vincentiis
Journal:  Clin Case Rep       Date:  2022-01-18

5.  Hemangiomas of the tongue and the oral cavity in a myotonic dystrophy type 1 patient: A case report.

Authors:  Simona Portaro; Antonino Naro; Claudio Guarneri; Giuseppe Di Toro; Alfredo Manuli; Rocco Salvatore Calabrò
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.